Introduction {#s1}
============

HPV DNA is present in 99.7% of all cervical cancer, the third most common cancer in women worldwide, with HPV types 16, 18, 31 and 45 being the most predominant HR-HPV types [@pone.0099109-Sudenga1]--[@pone.0099109-Ferlay1]. HPV is a common sexually transmitted infection and the majority of those infected are able to clear the infection naturally and only a small proportion will progress to cervical cancer [@pone.0099109-Ho1], [@pone.0099109-Moscicki1]. A persistent infection of a HR-HPV type is considered the most important factor for development of pre-cancer high-grade lesions and progression to cervical cancer [@pone.0099109-Sudenga2]; although, it is not a sufficient cause. Further, while cervical cancer is a definitive end to the stages of progression associated with HPV infection, it is important to understand the earlier biological processes of HPV persistence in the host.

The factors that lead to the development of a persistent HPV infection in some women, but not others, remain unclear. The role of host genetics that regulate biological mechanisms of immune response may contribute to the differential responses to infection and HPV clearance among women. To our knowledge, most research on host genetics including genome-wide association studies (GWAS) have focused on cervical cancer as the outcome [@pone.0099109-Shi1], [@pone.0099109-Chen1], and few have investigated the influence on HPV persistence, the intermediate phenotype to cervical cancer. Even with the limited genetic epidemiology studies of HPV infection as an outcome, the study designs have been predominantly cross-sectional, comparing genetic variants between women with HPV-positive cervical cancer and randomly selected controls [@pone.0099109-Demeret1], [@pone.0099109-Dong1]. Since persistence of HPV is time-dependent, longitudinal studies assessing HPV over time would be more appropriate to examine the true association. Several studies implicate immune evasion [@pone.0099109-Tindle1]--[@pone.0099109-Hildesheim1] involving genetically mediated determinants of the localized cell-mediated immune response in the host to be an important factor in the pathogenesis of HPV infection [@pone.0099109-Lee1], [@pone.0099109-Stanley1]. Specifically, human leukocyte antigens (HLA) variants (*DRB1\*13* and *DRB1\*1501-DQB1\*06*) have been shown to be associated with cervical cancer [@pone.0099109-Chen1], [@pone.0099109-Hildesheim2] and possibly HPV infection [@pone.0099109-Mahmud1]. Further, even among women who naturally clear HPV infection, there are differences in time to clearance suggesting the role of the host immune system. While HPV persistence is necessary for development of most cervical premalignant and cancers, the role of immune-related genes (such as those in the ImmunoChip) are biologically meaningful in relation to viral pathogenesis and may or may not be involved in the development or progression of pre-cancer lesions. The knowledge of immune response will complement our understanding of the pathogenesis of HPV. Our objective was to assess the association of host genetic variants in immune-related genes with clearance of HR-HPV using the Human ImmunoChip in HIV-positive African Americans, Hispanics, and European women.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

Written consent was obtained from all participants (parental written permission was obtained for minorities wherever required) and the study protocols for the parent study and this sub-study was approved by institutional review boards (IRB) at all sponsoring organizations and conformed to human-experimentation guidelines set forth by the United States Department of Health and Human Services. All protocols including the genetic work was finally reviewed and approved by the University of Alabama at Birmingham IRB.

Study Population {#s2b}
----------------

Participants from the HIV Epidemiology Research Study (HERS) cohort were included in this study [@pone.0099109-Koshiol1], [@pone.0099109-Smith1]. HERS is a multicenter, prospective study established by the Centers for Disease Control and Prevention (CDC) to examine the natural history of HIV in women. Women aged 16--55 with documented HIV status and high-risk behaviors were recruited between April 1993 and January 1995. The exclusion criteria in the parent study were as follows: i) had no identified HIV risk behavior; ii) had risk only by transfusion history or vertically from HIV-positive mother; iii) were not born female (i.e., transsexual); iv) did not consent to the full protocol, including pelvic exam, phlebotomy, and repeated HIV testing and counseling; and v) reported previously having AIDS-defining illnesses. Of the 1,994 women screened, 1,310 (66%) were enrolled in the study (871 HIV-positive and 439 HIV-negative). After enrollment, the core visit included a physical examination with complete gynecologic exam and specimen collection. Blood was tested for CD4+ T lymphocyte cells (CD4+) count and HIV viral load at 6-month intervals.

HPV DNA Detection and Classification {#s2c}
------------------------------------

HPV testing was performed on all HERS women at enrollment and every 6 months thereafter using cervicovaginal lavage samples. Viral DNA fragments from cervicovaginal lavage were amplified by using the consensus primers MY09/11 and HMB01 and were hybridized for a consensus probe and for 26 HPV types HR-HPV: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 and LR-HPV: 6, 11, 40, 42, 53, 54, 55, 83, and 84 using a chemiluminescent dot-blot format [@pone.0099109-Koshiol1]. PCR-based HPV data were classified as a) negative, b) positive for the specific types, or c) positive, type unknown if the sample was positive for the generic probe but not for a specific HPV type. PCR amplification of a human β-globin gene segment was used as an internal control for DNA quality; samples negative for this assay were excluded from analyses.

The analysis was performed in HIV-positive women in HERS who had no cervical treatment and were not pregnant during the follow-up. HIV-positive women with prevalent or incident HR-HPV infection who had peripheral blood mononuclear cells (PBMC) available at the baseline visit and at least one follow-up visit were included in the genetic analysis. In this study, the analyses focused on clearance of HR-HPV infections since these types are most likely to be associated with risk of pre-cancer and cancer of cervix and the models were adjusted for LR-HPV infections in order to account for the correlation between HPV subtypes. For the analysis, type-specific HPV status was assumed to remain unchanged across single missing visits. For women who tested negative for HPV at their last study visit, results were censored at that visit. Type-specific HPV clearance was defined as two consecutive HPV-negative tests to avoid the possibility of false-negative test results.

Genotyping {#s2d}
----------

Genomic DNA was extracted from stored PBMC and genotyped using the Human ImmunoChip, an iSelect HD custom genotyping array (Illumina, Inc.). The ImmunoChip is a custom SNP microarray developed by a consortium of specialists in the fields of immunology and inflammation. The microarray chip contains densely spaced 196,524 SNP variants (5,001 non-synonymous coding, 1,926 synonymous coding, and 4,065 in the untranslated region (UTR)), previously reported from GWAS and candidate gene studies of major autoimmune and inflammatory diseases [@pone.0099109-Cortes1], [@pone.0099109-Parkes1]. The genotyping of the samples was processed at two different laboratory facilities, and this was adjusted for in the statistical models.

Immunochip Genotype Calling and Quality Control {#s2e}
-----------------------------------------------

Data were analyzed using the Genome Studio Genotyping Module (Illumina, Inc.). The National Center for Biotechnology Information (NCBI) build 36 (hg18) map was used and the normalized probe intensities were extracted for all samples that passed standard laboratory quality-control (QC) thresholds. The Immunochip contains 763 duplicate SNPs and these were checked for concordance. Additionally, 174 genotyping assays failed which left 195,587 SNPs. All SNPs were checked for completeness (by SNP and by subject), rare variants, and deviation from Hardy-Weinberg Equilibrium (HWE) within each ethnic group separately. First, a large proportion of SNP assays failing on an individual may indicate poor quality of DNA sample and thus to avoid aberrant genotype calling, the threshold was set to 90% coverage. All African Americans and European Americans samples met this criterion, but 2 Hispanic samples did not and thus were removed from the analyses. Second, missing genotype data from a large number of individuals indicate poor assay quality for that SNP, and there were 5171 SNPs in African Americans, 5889 SNPS in European Americans and 6131 SNPs in Hispanics that were missing in more than 10% of individuals and were removed from the analysis. Third, there were 71,488 SNPs in African Americans, 73,017 in European Americans, and 68,264 in Hispanics that had a minor allele frequency less than 5% (rare variants) that were also removed in the analysis of each ethnic group, respectively. Fourth, there were 1234 SNPs in African Americans, 442 SNPs in European Americans, and 347 SNPs in Hispanics that deviated from HWE (p-value\<0.001), and thus were also removed from the analyses. Further, kinship between the individuals was also assessed in KING software [@pone.0099109-Manichaikul1], and two of the African American individuals were determined to be genetically related. However, one of the individuals had a lot of missing data and the relatedness seems likely due to specimen contamination; this individual was removed from the analyses (removal of both individuals did not change the results of the analysis). There were no major differences with the genotype call rates, minor allele frequency between the two genotyping facilities; however, they were adjusted for in all our analyses. After applying the QC methods above, there were 258 African Americans with 117,694 SNPs, 87 European Americans with 116,239 SNPs, and 55 Hispanics with 120,845 SNPs included in the analysis.

The same QC methods mentioned above for each ethnic group separately were then applied to the combined analysis which contained all three ethnic groups. For the combined analysis of all three distinct race (described below), there were 5190 SNPs removed because of low genotyping calls and an additional 66,536 rare variants (\<0.05%) across any one ethnic group and were removed; thus, 123,861 SNPs were available for analysis. Since SNPs in the ImmunoChip are mostly in the fine-mapped regions with high linkage disequilibrium (LD), correction for multiple testing was performed based on the effective number of tests which resulted after pairwise correlations between markers, as previously described [@pone.0099109-Moskvina1]. Based on this matrix, there were 94,307 effective tests among African Americans, 93,164 among European Americans, and 96,967 among Hispanics that resulted in adjusted p-value corrections of 5.30×10^−7^, 5.37×10^−7^, and 5.16×10^−7^, respectively. Additionally, among the SNPs common in all three ethnic groups, there were 80,510 effective numbers of tests (adjusted p value = and 6.21×10^−7^).

Statistical Analysis {#s2f}
--------------------

Cox proportional hazard models with the Wei-Lin-Weisfeld (WLW) extension [@pone.0099109-Xue1] were used to assess the influence of all SNPs (individually) with clearance of HR-HPV [@pone.0099109-Sudenga3]. This approach can simultaneously analyze time to HPV clearance of several types of HPV either at the same or different visits, taking into account possible correlation between the types and also has population-level interpretation [@pone.0099109-Sudenga2], [@pone.0099109-Xue1], making it appropriate for epidemiological studies. The WLW model was implemented in SAS using PHREG procedure, selecting the STRATA option to allow different baseline hazards function for each HPV type and robust variance.

To test for potential confounding effects of population stratification in our study cohort, principal component (PC) analysis was performed. Self-reported race (African Americans, European Americans, and Hispanics) was confirmed using clustering as implemented in EIGENSTRAT, and all individuals were confirmed with no apparent population outliers [@pone.0099109-Price1]. Hazard ratios (HR) and 95% confidence intervals were calculated for all races (n = 400) combined into one model (referred to as "race-adjusted analysis") adjusting for the first 10 PC values. Hazard ratios (HR) and 95% confidence intervals were also calculated for each race separately (African Americans (n = 258), European Americans (n = 87), and Hispanics (n = 55)) adjusting for the first three PC values. Further, a meta-analysis was using PLINK [@pone.0099109-Purcell1] pooling the results from individual race-specific analyses (referred to as "pooled analysis").

All SNP analyses were conducted using an additive genetic model, adjusting for CD4+ count, which served as a marker for immune status as well as a surrogate for HIV treatment. CD4+ count was adjusted for in the model at all visits when an individual was infected with HPV, which allowed CD4+ count to serve as a time-varying covariate. LR-HPV infections were adjusted for in the model when an individual was co-infected with any HR-HPV type, which also allowed LR-HPV to serve as a time-varying covariate when infection time overlapped. Quantile-quantile (Q-Q) plots of p-values were constructed to evaluate deviations from the expected test statistic distribution. ImmunoChip based Manhattan plots were generated to visualize the results.

Results {#s3}
=======

The average age at baseline of the 400 HIV-positive women included in the study was 34 years and their median baseline CD4+ count was 426.3 cells/mm^3^ \[interquartile range (IQR): 262.3--546.1 cells/mm^3^\]. Women were followed for a median time of 1,617 days (range 324--1729 days). Among the 400 women, there were 1052 HR-HPV infections, and 668 (64%) cleared during follow up. The most common HR-HPV types were HPV18 (n = 99), HPV16 (n = 88), HPV51 (n = 88), HPV58 (n = 83), and HPV52 (n = 79). Of the 668 infections that cleared during follow up, the average time to clearance was 457.9 days (median 322 days). Among the HR-HPV infections that cleared during follow-up, the average CD4+ count was 385.1 cells/mm^3^ (median 336.7 cells/mm^3^). Among the HR-HPV infections that persisted during follow-up, the average CD4+ count was 251.1 cells/mm^3^ (median 212.9 cells/mm^3^).

The Manhattan plots ([Figures 1A--D](#pone-0099109-g001){ref-type="fig"}) summarize the results from the association between HR-HPV clearance and the SNPs in the ImmunoChip (Q-Q plots - Figures S1A--D). All significant hits based on the K-effective method described above are presented for the three analytical models in [Table 1](#pone-0099109-t001){ref-type="table"} (race-adjusted analysis, race-specific analysis, and the pooled analysis). Results for all of the SNPs assessed can be found in [Table S1](#pone.0099109.s002){ref-type="supplementary-material"}. In the race-adjusted analysis, three SNPs that are in LD (rs1112085, rs11102637, and rs12030900) in the *MAGI3* gene were associated with HPV clearance. HIV-positive women infected with HR-HPV that have minor allele A for SNP rs1112085, located on chromosome 1, had a HPV clearance rate 1.51 times (p = 1.14×10^−07^) higher than those with the G wild type allele, controlling for CD4+ count, LR-HPV infection(s), 10 PCs, and genotyping facility ([Table 1](#pone-0099109-t001){ref-type="table"}). When assessing this SNP (rs1112085) in the three races separately ([Table 1](#pone-0099109-t001){ref-type="table"}), in African Americans and European Americans the minor allele was associated with higher clearance rates (HR = 1.49, p = 4.07×10^−05^, HR = 1.53, p = 0.01, respectively), while no association was detected between this SNP and HR-HPV clearance among Hispanics (HR = 0.98, p = 0.91). In the pooled analysis using the meta-analysis approach, the same minor allele was associated with higher clearance rates (HR = 1.33, p = 0.03). Likewise, a SNP (rs8031627), located on chromosome 15 in the *SMAD3* gene, was also significantly associated with higher clearance rates in the race-adjusted analysis (HR = 1.53, p = 8.04×10^−07^) and the pooled analysis (HR = 1.49, p = 1.78×10^−06^). When analyzed among the separate races, the SNP (rs8031627) was significantly associated with clearance in Hispanics (HR = 1.76, p = 0.0005) and African Americans (HR = 1.44, p = 0.003); a similar hazard ratio was seen in European Americans, but it was not statistically significant (HR = 1.34, p = 0.08).

![Manhattan plot showing the association P-values of single nucleotide polymorphisms (SNPs) in the ImmunoChip with the time to clearance of HR-HPV.\
The X-axes display the chromosome on which the SNP is located, the Y-axes display −log~10~ P-value. The dashed black line represents a significance level needed for multiple testing using the K effective method. Panel A.) Race-adjusted analysis B.) African Americans only C.) European Americans only, and D.) Hispanics only.](pone.0099109.g001){#pone-0099109-g001}

10.1371/journal.pone.0099109.t001

###### Cox proportional Hazard Ratios (HR) for the SNPS associated with time to clearance of high-risk (HR-HPV) HPV infection in the race-adjusted analysis, individual race-specific analysis, and pooled analysis of the three races separately.

![](pone.0099109.t001){#pone-0099109-t001-1}

                                                                                      Race-Adjusted   Hispanics   African Americans   European Americans   Pooled Analysis[\*](#nt101){ref-type="table-fn"}                                      
  ------------------------------------------------ ---- ----------- ---------------- --------------- ----------- ------------------- -------------------- -------------------------------------------------- ---------- ------ ---------- ------ ----------
  rs1112085                                         1    113742688      *MAGI3*           1.51        1.14E-07          0.98                 0.91                                1.49                         4.07E-05   1.53     0.01     1.33     0.03
  rs11102637                                        1    113793315      *MAGI3*           1.51        1.34E-07          0.98                 0.91                                1.47                         5.78E-05   1.53     0.01     1.33     0.03
  rs12030900                                        1    113775786      *MAGI3*           1.50        2.11E-07          0.98                 0.91                                1.47                         7.49E-05   1.53     0.01     1.32     0.03
  rs8031627                                         15   65271173       *SMAD3*           1.53        8.04E-07          1.76                0.0005                               1.44                          0.003     1.34     0.08     1.49   1.78E-06
  rs1633038                                         6    29848016       *HLA-G*           1.61         2.5E-05          0.79                 0.43                                1.89                         3.48E-07   1.35     0.20     1.34     0.22
  rs1125341                                         6    34894283      *UHRF1BP1*         0.85          0.01            0.96                 0.86                                0.93                           0.36     1.77   8.41E-08   1.18     0.51
  rs180327                                          11   116128869      *BUD13*           1.16          0.02            0.89                 0.48                                1.05                           0.62     0.50   7.52E-09   0.77     0.30
  rs619054                                          11   116166023      *APOA5*           0.85          0.03            1.03                 0.92                                1.03                           0.74     0.52   4.26E-07   0.81     0.41
  rs10952259                                        7    149764996      *GIMAP8*          1.14          0.03            1.62                 0.04                                1.01                           0.86     1.81   2.68E-07   1.42     0.12
  rs16852584                                        4    40582748       *APBB2*           1.10          0.45            0.53                 0.05                                1.06                           0.69     3.36   4.3E-07    1.25     0.63
  rs17511504[\*\*](#nt102){ref-type="table-fn"}     6    111737220   *LOC100128477*                                                                                                                                      4.33   6.07E-09         
  rs117611750[\*\*](#nt102){ref-type="table-fn"}    6    111892918      *REV3L*                                                                                                                                          4.13   5.11E-07         
  rs74833651[\*\*](#nt102){ref-type="table-fn"}     6    111894441      *REV3L*                                                                                                                                          4.13   5.11E-07         

\*using meta-analysis approach;

\*\*informative only in European Americans (e.g. MAF).

A SNP (rs1633038) located on chromosome 6 in the *HLA-G* gene region, was significantly associated with higher clearance rates (HR = 1.89, p = 3.48×10^−07^) in African Americans, although this was not observed in Hispanics or European Americans separately. Several other SNPs presented in [Table 1](#pone-0099109-t001){ref-type="table"} were significantly associated with clearance; however, to date, biological relevance of these SNPs and HPV is unclear.

Discussion {#s4}
==========

We report several variants in immune related genes that are associated with clearance of HR-HPV infection in African Americans, Hispanics, and European Americans HIV-positive women after accounting for the effects of CD4+ count, other LR-HPV co-infection(s), population stratification, and genotyping facility. In particular, CD4+ has been a major factor with HPV persistence/clearance among HIV patients; thus it was adjusted as a time-varying covariate. Also, none of the top hits in [table 1](#pone-0099109-t001){ref-type="table"} was associated with CD4+ change over time of infection, suggesting that these are independent SNP associations. The most significant association with time to clearance of HR-HPV in the adjusted analysis was seen with several SNPs located on chromosome 1 within the *MAGI3* gene region: rs1112085, rs11102637, and rs12030900 (in LD). The minor alleles for these SNPs in LD were associated with faster time (days) to clearance. MAGI-3 is part of the membrane-associated guanylate kinases (MAGUK) family of proteins that have inverted domain structure, and are part of the PDZ domain-containing proteins, which are localized between epithelial cells [@pone.0099109-Thomas1], [@pone.0099109-Ainsworth1]. The E6 protein of HPV inhibits cellular apoptosis or growth arrest [@pone.0099109-Doorbar1]. Several *in vivo* studies have shown that HR-HPV E6 proteins target MAGI-1,-2,-3 proteins for degradation [@pone.0099109-Thomas1], [@pone.0099109-Ainsworth1], [@pone.0099109-Glaunsinger1]. This degradation process appears to be necessary for cell transformation [@pone.0099109-Ainsworth1], [@pone.0099109-Simonson1]. Women in our cohort that had the minor allele for the SNPs in the intragenic region of MAGI-3 cleared the HPV infection faster than those with the major allele, and we hypothesize that these genetic variants may interact with HPV differently and therefore affect time to clearance.

Another interesting finding was that the minor allele for SNP rs8031627 located on chromosome 15 in the *SMAD3* gene was significantly associated with higher clearance rates in the adjusted analysis. SMAD proteins are signal transducers and transcriptional modulators that mediate multiple signaling pathways including TGF-β signals [@pone.0099109-Massague1], [@pone.0099109-Lee2], which inhibits the proliferation of most epithelial cells [@pone.0099109-Lee2]. The E7 protein of HPV has been shown *in vivo* to block SMAD3 by binding to its target sequence of DNA, which then also inhibits TFG-β for inhibiting DNA synthesis [@pone.0099109-Lee2]. Again, women in our cohort that had the minor allele for the SNP in UTR of SMAD3 cleared the HPV infection faster than those with the major allele. We hypothesize that the major allele variant may interact with HPV differently and therefore increase time to clearance.

Interestingly, the most significant association with time to clearance of HR-HPV in the African Americans analysis was with the SNP rs1633038 located on chromosome 6. The minor allele for SNP rs1633038 was associated with faster time (days) to clearance 1.9 times (HR = 1.89, p = 3.48×10^−7^) in that those that were homozygous for the minor allele had faster clearance compared to heterozygous and homozygous for the major allele. This SNP is located in chromosome 6 near the HLA-G gene region. HLA-G is a nonclassical HLA class Ib molecule that regulates the immune response through interaction with surface receptors on natural killer, T and antigen-presenting cells [@pone.0099109-Carosella1]--[@pone.0099109-Ferguson2]. Several studies have reported associations between HLA-G polymorphisms and HPV infection susceptibility and persistence [@pone.0099109-Ferguson1]--[@pone.0099109-Metcalfe1]. A 14 base pair deletion in the 3′ of HLA has also been shown to promote high-risk HPV infection and invasive cervical cancer in various populations [@pone.0099109-Bortolotti1]--[@pone.0099109-Silva1]. In our study we report an association between a SNP near the HLA-G region and HPV clearance; however, specific HLA-G alleles could not be determined through the available data in this region. While there were some differences in minor allele frequency of the variants in [table 1](#pone-0099109-t001){ref-type="table"} among the three races, there did not seem to be any correlation with the strength of direction of the associations. Further research is warranted to validate these findings and to determine the function of the SNP or if it is in LD with known SNPs in other studies.

We limited our analysis to clearance of HR-HPV infections since these types are most likely to be associated with cervical cancer risk. The underlying hypothesis with this approach is that the biology and pathogenesis of cancer-causing HR-HPV infections should be similar in relation to the host. While the model adjusted for the correlation between the HPV types, it did not produce hazard ratios specific to each HPV type. We were underpowered to assess HPV types separately; however the HERS cohort is one of the largest HIV-positive cohorts with over four years of HPV follow-up data in the United States. Our sample was comprised of 400 women (258 African Americans, 87 European Americans, and 55 Hispanics), which reduced the statistical power to detect significant findings after adjusting for multiple genetic testing, especially when analyzing the three races separately. However, we were able to observe several significant SNPs in the separate analyses for African Americans and European Americans. The ImmunoChip was designed for use in European populations and could be less informative for other ethnic groups if the disease-associated variants are not shared between them [@pone.0099109-Parkes1]. The sample sizes for European Americans and Hispanics were small, so any race specific associations need further evaluations in larger cohorts. Several SNPs that were significantly associated in multiple races independently seem interesting, even for smaller sample size. Few other SNPs have been shown to be significantly associated with HPV clearance in another cohort of HIV+ adolescents (REACH); however, most were not included in the ImmunoChip and of the few included (e.g. rs228942 and rs9292618) [@pone.0099109-Sudenga3], they were not significantly associated with HPV clearance in HERS. REACH comprised of adolescents also at early period of infection and HERS only had adults, mostly after several years of infection and thus may indicate different network of immune-related genes involved in the two scenarios and will need caution in interpretation requiring further research.

Of note, the Q-Q plot ([Figure S1](#pone.0099109.s001){ref-type="supplementary-material"} A--D) had high deviation (lamda values of 1.23, 1.49, and 1.57 in European Americans, African Americans and Hispanics, respectively) from the expected line. Caution is needed to interpret these associations as they might also be due to population stratification, repeated measures and the inter-relationships, the Cox proportional hazard model, or the nature of ImmunoChip SNPs that are in high LD within the fine-mapped regions, like MHC on chromosome 6 [@pone.0099109-Pearson1], [@pone.0099109-Juran1]. Women with multiple HPV infections were included in the Cox proportional hazard model with the WLW extension, which should account for the correlation between the individuals' data being used multiple times, but this could have an effect on the Q-Q plot due to the population substructure. The ImmunoChip has dense coverage of the MHC region as well as other regions so this may explain the deviation. Since the SNPs are close together, they are in high LD and therefore result in similar p-values. To our knowledge, the majority of genetic studies model the association using logistic regression, and the same assumptions of the Q-Q plot may not hold for the Cox proportional hazard model. The results could reflect a true association since we are assessing the association between a virus and immune related genes; therefore, we would expect a complex network of genes to play a role in clearance of HR-HPV and our significant findings are biologically plausible. Such an approach and methods have not been used often, specifically with high density SNP analyses; thus, it is difficult to interpret the actual reason of the observed deviations.

This analysis assessing SNPs in immune related genes and their associations with HR-HPV clearance brought forth hypotheses regarding several significant SNPs and gene regions. While these SNPs are associated with HPV clearance, future studies could examine if they are also associated with progression of pre-cancer neoplasia in larger cohorts with adequate events during follow-up periods. The variants in the current ImmunoChip are based on a consortium of genes involved in autoimmune diseases, and do not represent the comprehensive genes involved in human immunity. However, future research is needed to validate these associations and finemap the gene regions (which are not as dense in ImmunoChip for most regions) to identify one or multiple rare variants in LD with the functionally associated SNPs in ImmunoChip, specifically with *MAGI-3, SMAD3 and HLA-G* or other biologically plausible genes, potentially involved with HPV clearance.
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Quantile-quantile (Q-Q) plot showing the association P-values of single nucleotide polymorphisms (SNPs) in the ImmunoChip with the time to clearance of HR-HPV. The X-axes display the expected −log~10~ P-value, the Y-axes display the observed −log~10~ P-value.
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Results of Cox Proportional Hazard Ratios (HR) associated with time to clearance of high-risk (HR-HPV) HPV infection for all the SNPs in the ImmunoChip in the race-adjusted analysis (Adujsted), individual race-specific analysis (EA = European American, AA = African American, HIS = Hispanic), and pooled analysis (Meta Analysis) of the three races separately.
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